Sanofi's Dupixent was found to improve major symptoms in a three-year long-term follow-up of severe asthma patients while reducing the use of oral corticosteroids. The results of these studies were released at the 2022 ERS Annual Academic Conference held from the 4th to the 6th.

Through this conference, Dupixent released a number of data and RWE data confirming the improvement effect of asthma symptoms related to type 2 inflammatory biomarkers to solidify the treatment effect and safety profile in type 2 inflammatory severe asthma. It proved that it is a treatment that reduces the frequency of deterioration of severe asthma and lowers the severity, thereby helping to reach the treatment goal of severe a